A citation-based method for searching scientific literature

Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang, Eugene J Mark, Julie M Batten, Haiquan Chen, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, David P Carbone, Hongbin Ji, Jeffrey A Engelman, Mari Mino-Kenudson, William Pao, A John Iafrate. J Clin Oncol 2012
Times Cited: 1041



A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari, S C Wang, K D Wilner, J W Clark, S-H I Ou. Ann Oncol 2019
Times Cited: 134




List of shared articles



Times cited

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
0

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
0

Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C Cappelleri, D Ross Camidge. Future Oncol 2022
0

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
Xuehua Xie, Mengxing You, Erhong Meng, Shunyou Wang, Beifang Niu, Weiming Huang. J Cancer Res Clin Oncol 2022
0


Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
1

A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan.
Hsiang-Sheng Wang, Chien-Ying Liu, Sheng-Chi Hsu, Shih-Chiang Huang, Tsai-Hsien Hung, Kwai-Fong Ng, Tse-Ching Chen. Int J Mol Sci 2022
0

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
0

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Nikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, Jan Stratmann, Richard Riedel, Monica Schaefer, Jürgen Alt, Sylvia Gütz, Daniel C Christoph, Eckart Laack,[...]. Ther Adv Med Oncol 2021
9

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
18


Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.
Yoon Jung Jang, Dong-Gon Hyun, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji, Jae Cheol Lee. BMC Cancer 2021
1

Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Janna-Lisa Velthaus, Peter Iglauer, Ronald Simon, Carsten Bokemeyer, Peter Bannas, Niklas Beumer, Charles D Imbusch, Eray Goekkurt, Sonja Loges. Oncol Res Treat 2021
1

Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.
Maisam Makarem, Doreen A Ezeife, Adam C Smith, Janice J N Li, Jennifer H Law, Ming-Sound Tsao, Natasha B Leighl. Curr Oncol 2021
2

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
3


Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer.
Karim Amrane, Luca Campedel, Coline Le Meur, Ronan Abgral, Dris Kharroubi, Jacques Cadranel. Front Med (Lausanne) 2021
0

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Jaclyn M Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew Robinson, Elena Mow, James Keech, Kelvin K W Chan. BMC Cancer 2021
0

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
37